Results 91 to 100 of about 1,094,883 (299)

An Epidemiological Study of Neuropathic Pain Symptoms in Canadian Adults

Pain Research and Management, 2016
The reported prevalence of neuropathic pain ranges from 6.9% to 10%; however the only Canadian study reported 17.9%. The objective of this study was to describe the epidemiology of neuropathic pain in Canada.
Elizabeth G. VanDenKerkhof, Elizabeth G. Mann, Nicola Torrance, Blair H. Smith, Ana Johnson, Ian Gilron   +5 more
doaj   +1 more source

Pharmacological Treatment in Neuropathic Pain Management

, 2021
Neuropathic pain is a pain condition, usually chronic, in which an abnormal neural activity arises secondary to an injury, disease or some kind of dysfunction of the nervous system. Often neuropathic pain has complex symptoms – for instance, burning pain,
Atladottir, Nadia Lind
core  

Transcriptomic Profiling in Skeletal Muscle Identifies Associations With Knee Osteoarthritis: the Study of Muscle, Mobility and Aging (SOMMA)

Arthritis &Rheumatology, Accepted Article.
Objectives The association between skeletal muscle gene expression and knee osteoarthritis (OA) was examined among older adult participants of the Study of Muscle, Mobility and Aging (SOMMA). Methods Inclusion criteria included knee radiographs and bulk RNA sequencing (RNAseq) in vastus lateralis muscle, resulting in 523 participants (56% female ...
Daniel S. Evans, Tyler A. Mansfield, Gina M. Many, Tyler J. Sagendorf, Samaneh Farsijani, Bret H. Goodpaster, Lauren M. Sparks, Nancy E. Lane   +7 more
wiley   +1 more source

“I don’t know the correct way to describe it”: neuropathic pain experiences among athletes with spinal cord injury

BMJ Open Sport & Exercise Medicine
Background Chronic pain among athletes is often misinterpreted as tissue damage resulting from sport. While researchers have started to examine neuropathic pain among athletes with spinal cord injury (SCI), there is a need to develop a deeper ...
John Kramer, Kendra Todd, Kenedy Olsen, Kathleen Martin Ginis   +3 more
doaj   +1 more source

Antinociceptive activity of the S1P-receptor agonist FTY720 [PDF]

, 2008
FTY720 is a novel immunosuppressive drug that inhibits the egress of lymphocytes from secondary lymphoid tissues and thymus. In its phosphorylated form FTY720 is a potent S1P receptor agonist.
Geisslinger, Gerd, Gerd Geisslinger, Scholich, Klaus, Angioni, Carlo Federico, Klaus Scholich, Laura Popp, Sandra Pierre, Brenneis, Christian, Ovidiu Coste, Claudiu Marian, Marian, Claudiu, Popp, Laura, Coste, Ovidiu, Carlo Angioni, Schmidt, Helmut, Christian Brenneis, Pierre, Sandra, Helmut Schmidt   +17 more
core   +1 more source

Gabapentinoids‐duloxetine combination therapy for chronic pain: A mechanism oriented rational to bridge theoretical knowledge and real life setting

British Journal of Clinical Pharmacology, EarlyView.
Chronic pain represents a complex debilitating condition that extends beyond the protective function of physiological pain, often persisting as an independent disease entity. Chronic primary and secondary pain syndromes reflect a multifaceted continuum involving nociceptive, neuropathic and nociplastic mechanisms.
Stefania Nobili, Maurizio Evangelista, Elena Lucarini, Elena G. Giugliano, Carla Ghelardini, Laura Micheli, Lorenzo Di Cesare Mannelli   +6 more
wiley   +1 more source

The publication trend of neuropathic pain in the world and China: a 20–years bibliometric analysis

The Journal of Headache and Pain, 2018
Background There has been tremendous change on neuropathic pain research in the past 20 years in China and around the world. We analyzed the global trend of neuropathic pain research and compared China’s quantity and quality of neuropathic pain-related ...
Jishi Ye, Huang Ding, Juan Ren, Zhongyuan Xia   +3 more
doaj   +1 more source

Gabapentin as an add‐on analgesic to morphine in paediatric patients with chronic pain

British Journal of Clinical Pharmacology, EarlyView.
Aims Off‐label use of gabapentin for the treatment of chronic pain in children has increased over the last decade, with multiple clinical trials evaluating its role pain management and potential opioid‐sparing effects. To date, however, these studies appear to rely on empirical evidence without further consideration of pharmacokinetic‐pharmacodynamic ...
Paul Healy, Mariagrazia Felisi, Adriana Ceci, Oscar Della Pasqua, on Behalf of the GAPP Consortium, Corinne Alberti, Donato Bonifazi, Adriana Ceci, Thomas G. de Leeuw, Saskia N. de Wildt, Mariagrazia Felisi, Florentia Kaguelidou, Enora Le Roux, Rebecca Lundin, Laura Mangiarini, Dick Tibboel   +15 more
wiley   +1 more source

Translational development of crisugabalin for neuropathic pain

British Journal of Clinical Pharmacology, EarlyView.
Abstract Crisugabalin (HSK16149) is a next‐generation α2δ ligand developed to preserve the mechanistic rationale of gabapentinoids while refining target engagement and exposure‐related tolerability constraints. We performed a translational review of molecular/structural studies, in vivo pharmacology and behavioural safety assessments, phase I clinical ...
Rafael Batista João, Jilly Octoria Tagore Chan, Luísa Mendes Araújo, André Batista João, Raquel Mattos Filgueiras, Paulo César Ragazzo   +5 more
wiley   +1 more source

Initiation of Gabapentin with Opioids and Risk of Respiratory Cardiovascular and Opioid‐Related Adverse Events Following Surgery for Breast Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Pain is a key determinant of quality‐of‐life following breast cancer surgery, the most common cancer operation in the United States. Gabapentinoids are frequently prescribed for pain management, yet their respiratory, cardiovascular, and opioid‐related adverse effects remain unclear.
Jyun‐Heng Lai, Anton L V Avanceña, Juan P Cata, Jamie C. Barner, Sharon H. Giordano, Chanhyun Park, Hui Zhao, Kirk E. Evoy, John K. Lin, Jennifer C. Spencer, Mariana Chavez‐MacGregor, Kelly K. Hunt, Kerollos Nashat Wanis   +12 more
wiley   +1 more source